反应详情

2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid (Int-Vb, 25 mg, 0.058 mmol), (S)-2-aminopropanenitrile (Int-X, 6.09 mg, 0.087 mmol), HATU (28.7 mg, 0.075 mmol), and 4-methylmorpholine (23.45 mg, 0.232 mmol) were dissolved in DMF (1 mL). The reaction mixture was stirred for 1 h, and then purified by prep HPLC (PHENOMENEX® Luna 5u 21.2×250 mm gradient elution with Method 2—CH3CN/water containing 0.1% trifluoroacetic acid as defined above, 0% B to 100% B over 30 min, 20 mL/min, 220 nM, product retention=25.5 min) to provide single enantiomer N—((S)-1-cyanoethyl)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetamide (10 mg, 0.019 mmol, 32.1% yield): LCMS=484.0 [M+H]+; 1H NMR (400 MHz, methanol-d4) δ ppm 8.12-8.26 (2 H, m), 7.50-7.78 (7 H, m), 5.17 (1 H, s), 4.85-4.94 (1 H, m), 1.56 (3 H, d, J=7.26 Hz); HPLC peak RT=9.9 min (Method A).

1. custompurified by prep HPLC (PHENOMENEX® Luna 5u 21.2×250 mm gradient elution with Method 2—CH3CN/water containing 0.1% trifluoroacetic acid as defined above, 0% B to 100% B over 30 min, 20 mL/min, 220 nM, product retention=25.5 min)